Title: Repression of E-Cadherin by the Polycomb Group Protein EZH2 in Pancreatic Cancer
Abstract: Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer deaths in the United States. Single-agent gemcitabine remains the standard treatment for advanced PDA, which has shown improvement in disease-related symptoms and a modest benefit in survival. A recently discovered histone methyltransferase termed enhancer of zeste homologue 2 (EZH2) was found to be overexpressed in a variety of carcinomas including PDA. Silencing of E-cadherin was proposed as a mechanism by which EZH2 mediates tumor aggressiveness. Furthermore, in-vitro studies showed EZH2 depletion sensitizes pancreatic cancer cells to gemcitabine. In this study we correlated EZH2 with E-cadherin expression in PDA, and evaluated response to gemcitabine in relation to EZH2 expression.
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot